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ABSTRACT. The 67Ga31 complexes of three triazamacrocycles, 1,4,7-triazacyclononane-N,N*,N(-triacetic
acid (NOTA), its phosphonate analog 1,4,7-triazacyclononane-N,N*,N(-tris(methylenephosphonic) acid
(NOTP), and the monoethyl ester of NOTP, 1,4,7-triazacyclononane-N,N*,N(-tris (methylenephosphonate-
monoethylester) (NOTPME) were studied for possible use as radiopharmaceuticals. Biodistribution studies
and gamma imaging were performed in Wistar rats. The present results demonstrated that all the macrocyclic
complexes studied display renal clearance and are almost completely eliminated within 24 h. The
[67Ga](NOTP)32 chelate, with a large negative charge, has a considerably slower uptake and elimination by
the kidneys than the neutral [67Ga](NOTA) and [67Ga](NOTPME) chelates. We have thus demonstrated a
charge-clearance relationship for a series of stable and well characterized complexes. The high stability and
rapid renal excretion properties displayed by the NOTA and NOTPME chelates support their possible
application as imaging agents for kidney structural and functional studies. NUCL MED BIOL 26;6:707–710,
1999. © 1999 Elsevier Science Inc. All rights reserved.
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INTRODUCTION
The importance of complexes of gallium (III) in diagnostic nuclear
medicine has led to an increasing interest in its coordination
chemistry. The positron emitting radioisotope 68Ga (b1, t1/2 5 68
min) may be applicable in positron emission tomography (PET) (3,
14, 19), whereas 67Ga (b2,g, t1/2 5 3.35 days) is a useful tracer in
conventional nuclear medicine scintigraphy for tumor and inflam-
mation detection (14, 20–23).
When 67Ga31 is injected into the blood stream in the commonly
used form of gallium citrate (a weak chelate), the Ga31 ion is
transchelated to transferrin (13, 24, 25) and is then found in areas
of high iron uptake (bone marrow, liver, spleen, gastrointestinal
tract, salivary glands, and in the breast tissue of young adult or
lactating females [8]). The radioisotope is cleared slowly from the
body. A clinically useful chelating ligand should form inert com-
plexes with the appropriate metal ions, while at the same time
conferring to these complexes desirable chemical, physical, and
biological properties. Recently, there has been considerable interest
in polyaza macrocyclic ligands that form highly stable chelates with
trivalent metal ions, with slow rates of metal dissociation (1, 5–7,
10, 11, 13). The ligand 1,4,7-triazacyclononane-N,N9,N0-triacetic
acid (NOTA) has been found to fulfill the criteria of high
thermodynamic and kinetic stability for binding to Ga31. In fact,
the Ga(NOTA) chelate remains intact in nitric acid over a period
of 6 months (4).
In the present study, we investigated the in vivo behavior of
67Ga31 chelates of NOTA, its phosphonate analog 1,4,7-triazacy-
clononane-N,N9,N0-tris(methylenephosphonicacid) (NOTP), and
the monoethyl ester of NOTP, 1,4,7-triazacyclononane-N,N9,N0-
tris (methylenephosphonate monoethylester) (NOTPME) (see Fig.
1 for their chemical structures). The ligands form neutral (NOTA
and NOTPME) or negatively charged (NOTP) complexes with
67Ga31, which display varying molecular properties, which are
known to influence the biodistribution and excretion of substances
injected into the blood stream (5, 10, 18). These properties include
molecular size, molecular weight, charge, and hydrophilicity of the
complexes. Thus, the present study may be useful in assessing the
correlation between such chelate molecular properties and their in
vivo pharmacokinetics, helping in the design of new, more specific
radiopharmaceuticals.
MATERIALS AND METHODS
Materials, Reagents, and General Methods
[67Ga] citrate was obtained from CIS-Biointernational. The tri-
azamacrocyclic ligands NOTA, NOTP, and NOTPME were syn-
thesized and characterized by nuclear magnetic resonance (NMR)
spectroscopy as described elsewhere (11, 15, 16). Solutions of the
Ga31 chelates for NMR analysis were obtained by mixing stoichio-
metric amounts of Ga(NO3)3 and each of the ligands in D2O (at
20-mM concentrations) and adjusting the pH to 7 with diluted DCl
and NaOD. All the reagents and solvents were obtained from either
Aldrich or Sigma and used as received. 1H and 71Ga-NMR spectra
were recorded on a Varian Unity-500 Fourier Transform spectrom-
eter (at an external field of 11.8 T) operating at 499.8 and
152.4 MHz, respectively. The resonance shifts were measured
relative to tetrametylsilane (TMS) and the [Ga(H2O)6]
31 species
present in 0.1 M Ga(NO3)3 in D2O, respectively. Assignments of
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the proton NMR spectra were based on literature data on similar
systems and the results of two-dimensional homonuclear correlation
spectra (COSY) (2).
A gamma camera-computer system (GE 400 AC\STARPORT)
was used for acquisition and pre-processing. Data processing and
display were performed with a CityDesk IBM AT compatible
computer using software developed specifically for this type of
experiments. A well counter (DPC-Gamma C12) with a Compaq
DeskPro compatible computer was used for activity counting in the
biodistribution studies.
Gamma Imaging
Stock solutions of the ligands were prepared in isotonic HEPES pH
7 buffer and mixed (in a mole ratio of 1:1, with a small ligand
excess) with [67Ga] citrate. Gamma images and the biological
distribution for the three 67Ga31 complexes were determined using
Wistar rats weighing 300 g. All animal studies were carried out in
compliance with procedures approved by the appropriate institu-
tional review committees. Conscious rats were allowed free access of
food and water ad libitum. Three groups of four animals (one group
for each complex) were anaesthetized with Ketamine (50 mg/mL)/
chloropromazine (2.5%) (10:3) and injected in the tail vein with
ca. 150 mCi of the respective 67Ga31 chelate. The animals were
then positioned in ventral decubitus over the detector. Image
acquisition was initiated immediately before radiotracer injection.
Sequences of 180 images (10 s each), were acquired to 64 3 64
matrices. Blood samples were taken during the dynamic acquisition
and subsequently counted in a g well counter.
To analyze the transport of radiotracer over time, three regions of
interest (ROI) were drawn on the image files, corresponding to the
thorax, liver, and left kidney. From these ROI, time–activity curves
were obtained using homemade software. In addition, static data
were acquired at 24 and 48 h after the radiotracer injection.
Biodistribution Experiments
Four groups of four animals were injected with ca. 100 mCi of the
three 67Ga31 complexes and the [67Ga]citrate complex (for com-
parative purposes). All animals were sacrificed 2 h later. The majors
organs were removed, weighted, and counted in a g well counter.
Similar biodistribution studies were also performed with the rats
referred in the previous section sacrificed at 48 h.
RESULTS AND DISCUSSION
A series of structurally related 67Ga31 chelates of triazamacrocyclic
ligands with different types of pendant arms (Fig. 1), having
different molecular properties such as molecular weight and net
charge, were prepared aiming at the elucidation of structure–
activity relationships governing biodistribution and clearance of
67Ga31 complexes.
Figure 2 shows the averaged time–activity curves, obtained from
dynamic acquisitions for each ROI. The thorax activity/pixel was
considered as the background activity. The values of mean activity/
pixel for each ROI, after background deduction, were used to obtain
regional time–activity curves. The curves were normalized relative
to the maximum activity obtained for each complex. The com-
plexes studied seem to undergo different kidney clearance processes.
The liver–spleen curve is similar to the thorax curve, corresponding
only to blood activity. [67Ga](NOTA) and [67Ga](NOTPME),
show a much higher depuration efficiency and faster transit time
through the kidneys than [67Ga](NOTP)32. The kidney curve for
[67Ga](NOTP)32 indicates slow uptake and long retention of the
tracer by the organ.
Figure 3 illustrates the scintigraphic images obtained 30 min after
injection of the 67Ga31 chelates. For [67Ga](NOTA) and
[67Ga](NOTPME), only a slight activity in kidneys above the tissue
background was seen, but there was high activity in the bladder. In
contrast, a smaller background activity and no elimination of the
tracer after kidney retention was noticed for [67Ga](NOTP)32.
Almost all the radioactivity was cleared from tissues and organs
within 24 h (data not shown) and no deposition of the complexes
or any 67Ga31 particles in the liver–spleen region were observed.
All three Ga31 complexes were cleared rapidly from the blood
stream. In fact, 30 min after administration less than 0.03% of the
injected dose was found in the blood. This behavior suggests that
the chelates remained intact for the time interval they remained in
the blood. The results of animal biodistribution studies at 2 and 48 h
(in percent of injected dose per gram of organ) for [67Ga](NOTA),
[67Ga](NOTP)32, and [67Ga](NOTPME) are summarized in Figure
4, along with data for [67Ga] citrate for comparative purposes. These
results agree with the gamma-imaging data. They show clearly that,
as opposed to [67Ga] citrate, all the chelates studied were very
specific and underwent only renal clearance, similar to other blood
pool agents, e.g., [111In] DTPA (12). [67Ga]citrate has low tissue
specificity due both to transchelation of Ga31 to transferrin and
FIG. 1. Chemical structures of the ligands used in this
study.
FIG. 2. Time–activity curves at the various regions of interest for (A) [67Ga](NOTA), (B) [67Ga](NOTPME), and (C)
[67Ga](NOTP)32.
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formation of Ga(OH)4
2 colloids that were trapped by the reticulo
endothelial system (13, 24, 25).
This study demonstrates the high in vivo stability of the chelates.
We found no evidence of bone marrow accumulation, which is
observed when the gallium(III)-transferrin complex is formed (25).
The thermodynamic stability constant of Ga(NOTA) has been
reported elsewhere (log Kst 5 30.98 [6]) and is considerably higher
than that determined for the complex of Ga31 with transferrin (log
Kst 5 20.3 [13]), which is the main competitor for Ga
31 in serum
(13, 24, 25). The thermodynamic stability constant for
Ga(NOTP)32 has not been determined, but our solution studies by
71Ga NMR spectroscopy demonstrate that this complex remains
intact in aqueous solution, in the pH range of 2–11 (M.I.M. Prata
and C.F.G.C. Geraldes, manuscript in preparation). Other Ga31
complexes with triazamacrocyclic ligands, such as 1,4,7-tris(3,5-
dimethyl-2-hydroxybenzyl)-1,4,7-triazacyclononane and 1,4,7-
tris(2 mercaptoethyl)-1,4,7-triazacyclononane are formed with very
high in vitro and in vivo stability (7, 22). The triazamacrocycles
display an high conformational and size selectivity toward cations
and the high stability of these Ga31 complexes may arise from the
good fit of the metal ion (ionic radii 5 0.76 Å) in the triazacy-
clononane macrocycle cavity. All these ligands seem to encapsulate
the metal ion, insulating it efficiently from competing ligands.
None of the complexes passed through the blood–brain barrier,
as expected for nonlipophilic complexes (9, 17).
In conclusion, we found that the neutral chelates [67Ga]NOTA
and [67Ga]NOTPME have similar in vivo behavior, with high
stability and rapid renal excretion. The replacement of the carbox-
ylate pendant arms of NOTA by the methylenephosphonate mo-
noethylester groups of NOTPME seemed not to affect the biodis-
tribution and clearance of these complexes. However, the high
negatively charged chelate of the NOTP ligand, [67Ga](NOTP)32,
had a considerably slower uptake and elimination by the kidneys.
The main reason for this different in vivo behavior may be the
neutral versus negative charge of the complexes. The high stability
and rapid renal excretion of the NOTA and NOTPME chelates are
favorable properties for their possible application as kidneys imaging
agents, for both structural and functional studies.
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